ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC).

Berlin, J.; Catalano, Paul J.; Feng, Ying-Juan; Lowy, A. M.; Blackstock, A. William; Philip, P. A.; McWilliams, Robert R.; Abbruzzese, J. L.; Benson, Al B.

doi:10.1200/jco.2010.28.15_suppl.4034

Cited by 11 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because gemcitabine has been considered standard of care for systemic disease, and tends to be better tolerated that the "Mayo Clinic Regimen" of FU/FA, gemcitabinebased therapies have been the focus of most new trials. Use of biologic agents such as bevacizumab and cetuximab in conjunction with gemcitabine has been reported in a recent phase 2 trial, although neither arm of that trial warranted further development [32]. An important ongoing trial is RTOG 0848, a phase 3 trial evaluating gemcitabine alone versus gemcitabine plus erlotinib followed by a subsequent randomization to either completion of chemotherapy or consolidative chemoradiation after chemotherapy.…”

Section: Adjuvant and Neoadjuvant Therapymentioning

confidence: 96%

Current Treatment Options for Pancreatic Carcinoma

2011

View full text Add to dashboard Cite

Pancreas cancer is a significant cause of cancer mortality; therefore, the development of early diagnostic strategies and effective treatment is essential. Improvements in imaging technology, as well as use of biomarkers such as CA 19-9, are changing the way that pancreas cancer is diagnosed and staged. Although progress in treatment for pancreas cancer has been incremental, development of combination therapies involving both chemotherapeutic and biologic agents is ongoing. This article reviews current strategies in the diagnosis and treatment of resectable and advanced pancreas cancer.

show abstract

Section: Adjuvant and Neoadjuvant Therapymentioning

confidence: 96%

Current Treatment Options for Pancreatic Carcinoma

2011

View full text Add to dashboard Cite

show abstract

“…Collectively, these results suggest the absence of convincing evidence to suggest erlotinib has a role in the treatment of pancreas cancer. Nonetheless, the role of novel signal transduction inhibitors remains an area of interest in the adjuvant treatment [ 49 , 50 ].…”

Section: Adjuvant Therapy Following Resectionmentioning

confidence: 99%

Adjuvant therapy for pancreas cancer in an era of value based cancer care

Ahn

Williams

Goldstein

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

In resected pancreas cancer, adjuvant therapy improves outcomes and is considered the standard of care for patients who recover sufficiently post operatively. Chemotherapy or combined chemotherapy and radiation therapy (chemoradiation; CRT) are strategies used in the adjuvant setting. However, there is a lack of evidence to suggest whether the addition of RT to chemotherapy translates to an improvement in clinical outcomes. This is true even when accounting for the subset of patients with a higher risk for recurrence, such as those with R1 and lymph node positive disease. When considering the direct and indirect costs, impact on quality of life and questionable added clinical benefit, the true “net health benefit” from added RT to chemotherapy becomes more uncertain. Future directions, including the utilization of modern RT, integration of novel therapies, and intensifying chemotherapy regimens may improve outcomes in resected pancreas cancer.

show abstract

“…Monday – Friday throughout radiation to 50.4 Gy). While both arms were well tolerated, two-year overall survival was 35% for cetuximab and 37% for bevacizumab [29]. …”

Section: Additional Datamentioning

confidence: 99%

The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

Kimple¹,

Russo²,

Monjazeb³

et al. 2012

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Conflicting data and substantial controversy exist regarding optimal adjuvant treatment for those patients with resectable or potentially resectable adenocarcinoma of the pancreas. Despite improvements in short-term surgical outcomes, the use of newer chemotherapeutic agents, development of targeted agents, and more precise delivery of radiation, the 5-year survival rates for early stage patients remains less than 25%. This article critically reviews the existing data for various adjuvant treatment approaches for patients with surgically resectable pancreatic cancer. Our review confirms that despite several randomized clinical trials, the optimal adjuvant treatment approach for these patients remains unclear. Summary Despite improvements in short-term surgical outcomes, use of newer chemotherapeutic agents, development of targeted agents, and more precise delivery of radiation, the 5-year survival rates for early stage patients remains less than 25%. Despite several randomized clinical trials in these patients, the optimal treatment approach remains unclear. We review data the data regarding adjuvant therapy for patients with early stage pancreas cancer and discuss potential tumor factors that can be used to select patients for optimal adjuvant therapy. The probability of long-term survival is higher in patients who undergo margin-negative resections but local and distant failures are common, indicating the need for adjuvant therapies. Improved systemic treatment is desperately needed and the role of adjuvant radiation remains unclear. Neoadjuvant chemoradiation is being studied as an alternative to postoperative therapy. Potential molecular targets have been identified and the benefit of the addition of biologic agents to adjuvant treatments is being explored.

show abstract

ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC).

Cited by 11 publications

References 0 publications

Current Treatment Options for Pancreatic Carcinoma

Current Treatment Options for Pancreatic Carcinoma

Adjuvant therapy for pancreas cancer in an era of value based cancer care

The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer

Contact Info

Product

Resources

About